> top > docs > PubMed:32350928 > annotations

PubMed:32350928 JSONTXT

Annnotations TAB JSON ListView MergeView

PubMed_ArguminSci

Id Subject Object Predicate Lexical cue
T1 72-165 DRI_Background denotes There are currently no proven or approved treatments for coronavirus disease 2019 (COVID-19).
T2 166-350 DRI_Background denotes Early anecdotal reports and limited in vitro data led to the significant uptake of hydroxychloroquine (HCQ), and to lesser extent chloroquine (CQ), for many patients with this disease.
T3 351-571 DRI_Challenge denotes As an increasing number of patients with COVID-19 are treated with these agents and more evidence accumulates, there continues to be no high-quality clinical data showing a clear benefit of these agents for this disease.
T4 572-742 DRI_Approach denotes Moreover, these agents have the potential to cause harm, including a broad range of adverse events including serious cardiac side effects when combined with other agents.
T5 743-1084 DRI_Background denotes In addition, the known and potent immunomodulatory effects of these agents which support their use in the treatment of auto-immune conditions, and provided a component in the original rationale for their use in patients with COVID-19, may, in fact, undermine their utility in the context of the treatment of this respiratory viral infection.
T6 1085-1300 DRI_Outcome denotes Specifically, the impact of HCQ on cytokine production and suppression of antigen presentation may have immunologic consequences that hamper innate and adaptive antiviral immune responses for patients with COVID-19.
T7 1301-1564 DRI_Challenge denotes Similarly, the reported in vitro inhibition of viral proliferation is largely derived from the blockade of viral fusion that initiates infection rather than the direct inhibition of viral replication as seen with nucleoside/tide analogs in other viral infections.
T8 1565-1848 DRI_Challenge denotes Given these facts and the growing uncertainty about these agents for the treatment of COVID-19, it is clear that at the very least thoughtful planning and data collection from randomized clinical trials are needed to understand what if any role these agents may have in this disease.

LitCovid-OGER-BB

Id Subject Object Predicate Lexical cue
T1 23-41 CHEBI:5801 denotes hydroxychloroquine
T2 23-41 DG_20 denotes hydroxychloroquine
T3 23-41 CHEBI:5801 denotes hydroxychloroquine
T4 62-70 SP_7 denotes COVID-19
T5 129-140 NCBITaxon:11118 denotes coronavirus
T6 155-163 SP_7 denotes COVID-19
T7 249-267 CHEBI:5801 denotes hydroxychloroquine
T8 249-267 DG_20 denotes hydroxychloroquine
T9 249-267 CHEBI:5801 denotes hydroxychloroquine
T10 296-307 CHEBI:3638 denotes chloroquine
T11 296-307 DG_10 denotes chloroquine
T12 296-307 CHEBI:3638 denotes chloroquine
T13 392-400 SP_7 denotes COVID-19
T14 424-430 CHEBI:36357 denotes agents
T15 424-430 CHEBI:36357 denotes agents
T16 588-594 CHEBI:36357 denotes agents
T17 588-594 CHEBI:36357 denotes agents
T18 689-696 UBERON:0000948 denotes cardiac
T19 735-741 CHEBI:36357 denotes agents
T20 735-741 CHEBI:36357 denotes agents
T21 811-817 CHEBI:36357 denotes agents
T22 811-817 CHEBI:36357 denotes agents
T23 867-873 UBERON:0002405 denotes immune
T24 968-976 SP_7 denotes COVID-19
T25 1068-1073 NCBITaxon:10239 denotes viral
T26 1159-1166 CHEBI:59132 denotes antigen
T27 1159-1166 CHEBI:59132 denotes antigen
T28 1159-1179 GO:0019882 denotes antigen presentation
T29 1226-1232 GO:0045087 denotes innate
T30 1237-1245 GO:0051866 denotes adaptive
T31 1256-1262 UBERON:0002405 denotes immune
T32 1291-1299 SP_7 denotes COVID-19
T33 1348-1353 NCBITaxon:10239 denotes viral
T34 1348-1367 GO:0006260 denotes viral proliferation
T35 1408-1413 NCBITaxon:10239 denotes viral
T36 1408-1420 GO:0006260 denotes viral fusion
T37 1483-1488 NCBITaxon:10239 denotes viral
T38 1483-1500 GO:0006260 denotes viral replication
T39 1514-1524 CHEBI:23447 denotes nucleoside
T40 1514-1524 CHEBI:23447 denotes nucleoside
T41 1547-1552 NCBITaxon:10239 denotes viral
T42 1651-1659 SP_7 denotes COVID-19
T43 1816-1822 CHEBI:36357 denotes agents
T44 1816-1822 CHEBI:36357 denotes agents
T45 1935-1941 CHEBI:52217 denotes agents
T46 1935-1941 CHEBI:52217 denotes agents
T47 1963-1971 SP_7 denotes COVID-19

hydroxychloroquine

Id Subject Object Predicate Lexical cue hp_id
T1 862-884 Phenotype denotes auto-immune conditions http://purl.obolibrary.org/obo/HP_0002960